Inovio Pharmaceuticals

Yahoo Finance • last year

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Received FD... Full story

Yahoo Finance • last year

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN D... Full story

Yahoo Finance • 2 years ago

Inovio Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

Inovio Pharmaceuticals (NASDAQ:INO) First Quarter 2023 Results Key Financial Results Revenue: US$114.9k (down 42% from 1Q 2022). Net loss: US$40.6m (loss narrowed by 49% from 1Q 2022). US$0.16 loss per share (improved from US$0.36 loss i... Full story

Yahoo Finance • 2 years ago

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developi... Full story

Yahoo Finance • 2 years ago

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa., April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to... Full story

Yahoo Finance • 2 years ago

INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

PLYMOUTH MEETING, Pa., Oct. 25, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with... Full story

Yahoo Finance • 2 years ago

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial INO-3107 demonstrated stat... Full story

Yahoo Finance • 2 years ago

After Slashing Costs, Is Inovio a Buy?

Inovio Pharmaceuticals (NASDAQ: INO) was once one of the biggest coronavirus-vaccine hopefuls. The company was among the first to launch clinical trials of a vaccine candidate -- and saw its shares soar more than 700% in the first half of... Full story

Yahoo Finance • 2 years ago

Inovio to reduce its workforce by 18%

Inovio Pharmaceuticals Inc. said Tuesday that it plans to reduce its full-time workforce by 18% and its contractor workforce by 86% in an effort to extend its cash runway. The company had 317 full-time employees in 2021. Inovio, which stil... Full story

Yahoo Finance • 2 years ago

Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options

This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study results for an experimental angina drug, tw... Full story

Yahoo Finance • 2 years ago

Why Inovio Pharmaceuticals Stock Topped the Market on Monday

Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Previous to that, he worked in various pos... Full story

Yahoo Finance • 2 years ago

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV... Full story